IV Sodium Ferric Gluconate Complex in Patients Undergoing TAVI
Status:
Recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
Iron deficiency is common among patients undergoing TAVI. It is estimated at 54-79%. Previous
non-randomized small trial have shown symptomatic benefit in treating iron deficiency in this
group of patients.
The investigators predict, that as IV iron will improve symptoms, quality of life and
exercise tolerance in this group of patients.